Advertisement Novasep gets FDA nod for two synthesis sites in 2011 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Novasep gets FDA nod for two synthesis sites in 2011

Novasep, a French manufacturing solutions provider, has received the US Food and Drug Administration (FDA) green signal for two of its Synthesis sites, Freeport (the Bahamas) facility in March and Chasse sur Rhone (Lyon, France) facility in May, this year.

Chasse-sur-Rhone provides for process scale-ups, the supply of clinical batches and the regular production of low volume compounds under cGMP.

Freeport site performs custom manufacturing services from late stage clinical trials through to multi-ton commercial production for API’s

Novasep Synthesis president Patrick Glaser said their scope of synthesis and purification technologies and know-how enables them to produce the increasingly complex molecules with purity.

Novasep Synthesis is the synthetic molecule contract manufacturing division of Novasep.